IMM-H004 therapy for permanent focal ischemic cerebral injury via CKLF1/CCR4-mediated NLRP3 inflammasome activation.
RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMaleAdministered 6 hours after onset of ischaemia
Model: Permanent middle cerebral artery occlusion (pMCAO) model of focal cerebral ischaemia
IMM-H004 provided significant protection against permanent focal ischaemic injury in rats through a CKLF1-dependent anti-inflammatory pathway. It reduced CKLF1 binding to CCR4, suppressed NLRP3 inflammasome activation and the ensuing inflammatory response, and protected the ischaemic brain, support…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.